Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 28

1.

Pharmaceutical Approval Update.

Kaufman MB.

P T. 2018 Sep;43(9):528-530.

2.
3.

Attenuation of early phase inflammation by cannabidiol prevents pain and nerve damage in rat osteoarthritis.

Philpott HT, OʼBrien M, McDougall JJ.

Pain. 2017 Dec;158(12):2442-2451. doi: 10.1097/j.pain.0000000000001052.

4.

Training and Practices of Cannabis Dispensary Staff.

Haug NA, Kieschnick D, Sottile JE, Babson KA, Vandrey R, Bonn-Miller MO.

Cannabis Cannabinoid Res. 2016 Dec 1;1(1):244-251. doi: 10.1089/can.2016.0024. eCollection 2016.

6.

Transdermal cannabidiol reduces inflammation and pain-related behaviours in a rat model of arthritis.

Hammell DC, Zhang LP, Ma F, Abshire SM, McIlwrath SL, Stinchcomb AL, Westlund KN.

Eur J Pain. 2016 Jul;20(6):936-48. doi: 10.1002/ejp.818. Epub 2015 Oct 30.

7.

HU-444, a Novel, Potent Anti-Inflammatory, Nonpsychotropic Cannabinoid.

Haj CG, Sumariwalla PF, Hanuš L, Kogan NM, Yektin Z, Mechoulam R, Feldmann M, Gallily R.

J Pharmacol Exp Ther. 2015 Oct;355(1):66-75. doi: 10.1124/jpet.115.226100. Epub 2015 Aug 13.

8.

The cation channel Trpv2 is a new suppressor of arthritis severity, joint damage, and synovial fibroblast invasion.

Laragione T, Cheng KF, Tanner MR, He M, Beeton C, Al-Abed Y, Gulko PS.

Clin Immunol. 2015 Jun;158(2):183-92. doi: 10.1016/j.clim.2015.04.001. Epub 2015 Apr 11.

9.

[Marihuana and cannobinoids as medicaments].

Tkaczyk M, Florek E, Piekoszewski W.

Przegl Lek. 2012;69(10):1095-7. Review. Polish.

PMID:
23421098
10.

The abnormal cannabidiol analogue O-1602 reduces nociception in a rat model of acute arthritis via the putative cannabinoid receptor GPR55.

Schuelert N, McDougall JJ.

Neurosci Lett. 2011 Aug 1;500(1):72-6. doi: 10.1016/j.neulet.2011.06.004. Epub 2011 Jun 13.

PMID:
21683763
11.

Cannabidiol as an emergent therapeutic strategy for lessening the impact of inflammation on oxidative stress.

Booz GW.

Free Radic Biol Med. 2011 Sep 1;51(5):1054-61. doi: 10.1016/j.freeradbiomed.2011.01.007. Epub 2011 Jan 14. Review.

12.

Therapeutic Potential of Non-Psychotropic Cannabidiol in Ischemic Stroke.

Hayakawa K, Mishima K, Fujiwara M.

Pharmaceuticals (Basel). 2010 Jul 8;3(7):2197-2212. Review.

13.

Cannabidiol: from an inactive cannabinoid to a drug with wide spectrum of action.

Zuardi AW.

Braz J Psychiatry. 2008 Sep;30(3):271-80. Review.

14.

Cannabinoids in the management of difficult to treat pain.

Russo EB.

Ther Clin Risk Manag. 2008 Feb;4(1):245-59.

15.

Therapeutic potential of cannabinoid-based drugs.

Klein TW, Newton CA.

Adv Exp Med Biol. 2007;601:395-413. Review.

PMID:
17713029
16.

Cannabis, pain, and sleep: lessons from therapeutic clinical trials of Sativex, a cannabis-based medicine.

Russo EB, Guy GW, Robson PJ.

Chem Biodivers. 2007 Aug;4(8):1729-43. Review.

PMID:
17712817
17.

Combined cannabinoid therapy via an oromucosal spray.

Perez J.

Drugs Today (Barc). 2006 Aug;42(8):495-503. Review.

PMID:
16969427
18.

Cannabidiol lowers incidence of diabetes in non-obese diabetic mice.

Weiss L, Zeira M, Reich S, Har-Noy M, Mechoulam R, Slavin S, Gallily R.

Autoimmunity. 2006 Mar;39(2):143-51.

PMID:
16698671
19.

The use of a cannabis-based medicine (Sativex) in the treatment of pain caused by rheumatoid arthritis.

Wright S, Ware M, Guy G.

Rheumatology (Oxford). 2006 Jun;45(6):781; author reply 781-2. Epub 2006 Apr 18. No abstract available.

PMID:
16621924
20.

Preliminary assessment of the efficacy, tolerability and safety of a cannabis-based medicine (Sativex) in the treatment of pain caused by rheumatoid arthritis.

Blake DR, Robson P, Ho M, Jubb RW, McCabe CS.

Rheumatology (Oxford). 2006 Jan;45(1):50-2. Epub 2005 Nov 9.

PMID:
16282192

Supplemental Content

Loading ...
Support Center